HIGHLIGHTS
- who: Denisa Baci from the General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy have published the Article: Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients, in the Journal: (JOURNAL)
- how: Five randomized phase II-III trials testing three ICIs (nivolumab pembrolizumab and atezolizumab) all showed a clinically and statistically significant advantage over the same standard comparator docetaxel ICIs were tested in locoregional NSCLC.
- future: The ability to increase the clinical benefit for higher numbers of NSCLC patients and preventing . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.